Cancer Chemotherapy and Pharmacology

, Volume 29, Issue 4, pp 321–322 | Cite as

Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus

  • Andreas Harstrick
  • Carsten Bokemeyer
  • Peter Preusser
  • Claus Henning Köhne-Wömpner
  • Hans-Joachim Meyer
  • Michael Stahl
  • Heike Knipp
  • Hans-Joachim Schmoll
  • Hansjochen Wilke
Original Articles Single-Agent Etoposide, Metastatic Squamous-Cell Carcinoma, Esophagus

Summary

A total of 26 evaluable patients presenting with advanced or metastatic squamous-cell carcinoma of the esophagus were entered in a phase II trial to assess the single-agent activity of etoposide. Etoposide was given at a dose of 200 mg/m2 on 3 consecutive days every 3 weeks. Five patients (19%) achieved a partial response and seven (27%) experienced stabilisation of their disease. The median duration of response was 4 months (range 3–8 months). The major toxicity was leukopenia, which reached WHO grade 3 in 46% of patients and grade 4 in 11% of cases, with five instances of leukopenic fever and one therapy-associated death being recorded. Etoposide given at this dose and on this schedule seems to have considerable activity against non-pretreated metastatic esophageal carcinoma.

Keywords

Carcinoma Cancer Research Partial Response Etoposide Median Duration 

References

  1. 1.
    Coonley C, Bains M, Heelan R, Dukeman M, Kelsen DP (1983) Phase II study of etoposide in the treatment of esophageal carcinoma. Cancer Treat Rep 67:397Google Scholar
  2. 2.
    Engström P, Lavin PT, Klaasen OJ (1983) Phase II evaluation of mitomycin and cisplatin in advanced esophageal carcinoma. Cancer Treat Rep 67:713Google Scholar
  3. 3.
    Ezdinli EZ, Gelber R, Desai DV, Falkson G, Moertel CG, Hahn RG (1980) Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience. Cancer 46:2149Google Scholar
  4. 4.
    Kelsen DP (1984) Chemotherapy of esophageal cancer. Semin Oncol 11:159Google Scholar
  5. 5.
    Kelsen DP, Bains MS, Cvitkovic E (1979) Vindesine in the treatment of esophageal carcinoma: a phase II study. Cancer Treat Rep 63:2019Google Scholar
  6. 6.
    Panettiere F, Leichman L, Tilchen E (1984) Chemotherapy for advanced epidermoid carcinoma of the esophagus with single agent cisplatin: final report of a Southwest Oncology Group study. Cancer Treat Rep 68:1023Google Scholar
  7. 7.
    Radice R, Bunn P, Ihde D (1979) Therapeutic trials with VP-16 and VM-26. Cancer Treat Rep 63:1231Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • Andreas Harstrick
    • 1
    • 2
  • Carsten Bokemeyer
    • 1
    • 2
  • Peter Preusser
    • 4
  • Claus Henning Köhne-Wömpner
    • 1
    • 2
  • Hans-Joachim Meyer
    • 1
    • 2
  • Michael Stahl
    • 3
  • Heike Knipp
    • 1
    • 2
  • Hans-Joachim Schmoll
    • 1
    • 2
  • Hansjochen Wilke
    • 3
  1. 1.Department of Hematology and OncologyUniversity of Hannover Medical SchoolHannover 61FRG
  2. 2.Department of Abdominal SurgeryUniversity of HannoverHannoverFRG
  3. 3.Department of OncologyWest German Cancer CenterEssenFRG
  4. 4.Department of SurgeryUniversity of MuensterMuensterFRG

Personalised recommendations